SUBSCRIBE
SUBSCRIBE
News   Policy

FDA Wants More Data Before Approving Clinical Cell Culture Ltd.'s ReCell

January 16, 2006 | 
1 min read
Tissue engineering specialist Clinical Cell Culture's (ASX:CCE, C3) share price took a blow today, in the wake of a request by the US Food and Drug Administration (FDA) for more performance data before it can approve C3's ReCell for sale in the US.
Regulatory Australia
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Podcast
Lilly’s Foundayo Nod Launches New Battle With Novo, M&A Mania Continues, Tariffs Hit Pharma
April 8, 2026
 · 
1 min read
 · 
Heather McKenzie
Many various colored tablets and pills are stacked in shopping cart, percent signs are around. Concept of buying of medicines, online sales of medication, discounts and promotions in pharmacy
Drug pricing
AbbVie Puts Humira on TrumpRx at Steep Discount as Tariff Threat Solidifies
April 7, 2026
 · 
1 min read
 · 
Tristan Manalac
Successful businessman standing in front of multiple pathways, making a decision for the right move. A symbol of great investment and positive progress in the development of business. stock illustration
Government
FDA’s 2027 Budget Proposes Permanent Rare Disease Vouchers, Easier Entry to Clinic
April 7, 2026
 · 
3 min read
 · 
Tristan Manalac
Insights
Lean Derisking: Smart Ways to Cross Drug Development’s “Valley of Death”
April 6, 2026
 · 
4 min read
 · 
Jennifer C. Smith-Parker